Observed Signal · Oct 4, 2026 · Technical Release · Source: PR Newswire: Technology News · Impact: 2/5 · Sentiment: Neutral
SIBIONICS and PharmaSens Explore Automated Insulin Delivery at EASD 2026
At the EASD 2026 congress in Milan, SIBIONICS presented its vision for the future of diabetes care under the theme "See More, Act Earlier," featuring exhibits on glucose, ketone, and combined monitoring, multi-modal sensing, and broader biosensor applications. The company also held an industry symposium on new technologies shaping diabetes care. Central to the discussions was the niia signature, a research device co-developed with PharmaSens that combines continuous glucose monitoring, insulin delivery, and an automated glucose control algorithm. Early findings from the SMART02 feasibility study showed that insulin delivery near the sensor caused only rare and transient interference, with full signal recovery about 20 minutes after bolus administration. The device, still in early prototype stage, is not approved for sale in any market. The collaboration aims to simplify automated insulin delivery by integrating multiple functions into a single wearable device.
News about a medical device collaboration, not directly relevant to AdTech/MarTech/AI industry, but may be of interest for health-tech tracking.
Track Real-Time Medical Technology Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- SIBIONICS presented at EASD 2026 in Milan on October 4, 2026.
- SMART02 feasibility study evaluated an early prototype of niia signature, a combined CGM and insulin pump.
- Insulin delivery near the sensor caused rare transient interference, with full signal recovery about 20 minutes after bolus.
- niia signature is a research device, not approved for sale in any market.
- The collaboration between SIBIONICS and PharmaSens began in June 2025.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Cumulus Neuroscience Presents CNS Trial Data at ISCTM 2026
Cumulus Neuroscience presented three posters at the ISCTM 2026 Autumn Conference in Philadelphia, showcasing interim data on its NeuLogiq platform. The studies demonstrated high patient adherence and usability for remote multimodal brain monitoring in borderline personality disorder (BPD) and therapy-resistant depression. Additionally, a two-minute digital cognitive task (Symbol Swap) performed comparably to established clinical benchmarks for Alzheimer's trial pre-enrichment. The findings suggest that frequent digital measurement is feasible and acceptable, potentially enabling shorter, less burdensome CNS trials without compromising sensitivity. Cumulus Neuroscience developed the NeuLogiq platform in collaboration with 10 top biopharma companies to facilitate decentralized clinical trials.
LG CNS Showcases Pharma-Specific Manufacturing AX at CPHI Milan 2026
LG CNS, a Korean AI transformation company, showcased its pharma-specific manufacturing AX solutions at CPHI Milan 2026, the world's largest pharma-biotech exhibition. The company presented three smart factory solutions under the theme 'Autonomous Factory in Pharma': Factova Worldworks, a digital twin-based virtual validation simulator for factory design; Factova Control, a data standardization and equipment control solution for production operations; and a quality management solution that uses AI to detect anomalies and automate the Annual Product Quality Review (APQR). LG CNS is the only Korean company participating in the newly created 'AI & Tech' zone. The solutions aim to support pharma and biotech companies in optimizing factory design, production operations, and quality management.
ArisGlobal Unveils XDI: Revolutionizing Life Sciences Data Intelligence
ArisGlobal announced XDI, its Data Intelligence Cortex, at the Breakthrough 2026 event. XDI is presented as a federated data-intelligence platform for life sciences that leaves data in place while unifying meaning and delivering explainable, decision-grade insights across the product lifecycle. The platform targets cross-domain reasoning and auditability across clinical, pharmacovigilance, regulatory, medical affairs, quality, and benefit-risk functions. Initial offerings focus on pharmacovigilance operational intelligence, benefit-risk intelligence, and regulatory operational intelligence, with ArisGlobal citing substantial efficiency and quality-control improvements (percentage reductions presented by the company). XDI is built on a “Trust by Design” approach and integrates ArisGlobal’s NavaX AI governance to provide embedded auditability and regulatory defensibility across the AI lifecycle.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.